Have there been reports that COVID‑19 vaccination can trigger ocular flares in patients with Behçet’s disease?

COVID-19 Vaccination Can Trigger Ocular Flares in Behçet's Disease Patients

Yes, there are documented reports of COVID-19 vaccination triggering ocular flares in patients with Behçet's disease, though such events appear to be rare. The evidence shows that while autoimmune flares post-vaccination can occur, the benefits of vaccination generally outweigh these risks, and most flares are manageable with corticosteroids.

Evidence of Vaccine-Triggered Ocular Inflammation

The most direct evidence comes from a case report of a 30-year-old man who developed panuveitis as the initial presentation of Behçet's disease following mRNA COVID-19 vaccination (Moderna) 1. Notably, he experienced a second episode of panuveitis after the second vaccine dose, both episodes responding to corticosteroid treatment. This temporal relationship—occurring twice with repeated vaccine exposure—suggests a potential causative link rather than mere coincidence.

More broadly, systematic reviews document that uveitis is the most common ocular complication following COVID-19 vaccination, with cases reported across multiple vaccine platforms 2. Among 107 documented cases of ocular complications post-vaccination, inflammatory conditions predominated, with Pfizer-BioNTech and Oxford-AstraZeneca vaccines most frequently implicated 2.

Context from Autoimmune Disease Guidelines

Guidelines addressing rheumatologic and autoimmune conditions acknowledge that COVID-19 vaccines can trigger autoimmune disease flares, though the evidence remains limited 3. The 2022 vaccination recommendations note that "it is currently unknown whether Covid‐19 vaccines can" trigger flares in rheumatology patients, but emphasize that vaccination should proceed when underlying disease is controlled 3.

The 2025 British Society of Gastroenterology guidelines provide the most explicit acknowledgment, stating that "several cases of an acute AIH-like illness have been reported within 4 weeks of COVID-19 vaccination" with both viral vector and mRNA vaccines 4. While this addresses hepatic rather than ocular manifestations, it establishes precedent for vaccine-triggered autoimmune flares.

Clinical Implications and Risk Stratification

Key Points for Behçet's Patients:

• Disease flares post-vaccination are typically mild and respond to corticosteroids 1, 5
• Most ocular complications are self-limiting, though some involve reactivation of preexisting inflammatory disease 2
• Timing matters: Symptoms typically occur within 4 weeks of vaccination 4
• Repeated exposure can trigger recurrence: The Behçet's case demonstrated flares after both first and second doses 1

Monitoring Strategy:

• Counsel patients about potential ocular symptoms (pain, redness, vision changes, photophobia) before vaccination
• Advise seeking immediate ophthalmologic evaluation if symptoms develop within 30 days post-vaccination
• Consider extended monitoring (at least 2 hours) post-vaccination for patients with active or recent ocular inflammation 3
• Ensure disease is well-controlled before vaccination when possible 3

Balancing Risk vs. Benefit

Despite these reports, vaccination remains strongly recommended for Behçet's patients. The evidence shows:

• COVID-19 infection itself poses greater risk than vaccination in immunosuppressed patients 4
• Vaccine-triggered flares are manageable with standard immunosuppressive therapy 1
• The incidence is low: Even in broader autoimmune populations, post-vaccine complications remain rare 4

Common Pitfalls to Avoid:

1. Don't withhold vaccination due to fear of flares—the risk of severe COVID-19 outweighs flare risk
2. Don't assume all post-vaccination symptoms are vaccine-related—rule out actual COVID-19 infection and other causes 3
3. Don't delay treatment if ocular symptoms develop—early corticosteroid intervention is key 1

Medication Management Considerations

For Behçet's patients on immunosuppression, general rheumatology guidelines suggest 3:

• Corticosteroids: Taper to <10 mg/day before vaccination if disease allows
• Anti-TNF agents: No specific dose adjustment required
• Timing: Vaccinate when disease is stable rather than during active flare

The 2021 EULAR guidance on IL-1 mediated autoinflammatory diseases notes that "vaccination may lead to a disease flare" but emphasizes that "benefits generally outweigh the potential risks" 6.

Bottom Line

Proceed with COVID-19 vaccination in Behçet's patients with ocular involvement, but counsel them about the small risk of triggering an ocular flare. Ensure they know to seek immediate ophthalmologic care if symptoms develop within 30 days post-vaccination. Have a low threshold for initiating corticosteroid therapy if uveitis develops, as documented cases have responded well to this approach 1.